Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-Dose Oral Tizanidine Premedication for Laryngeal Mask Airway Insertion Conditions and Ambulatory Recovery Quality in Sevoflurane-Based Anesthesia: A Randomized Double-Blind Placebo-Controlled Trial

NCT07921602 is registered in ClinicalTrials.gov with Beni-Suef University as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07921602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Single-Dose Oral Tizanidine Premedication for Laryngeal Mask Airway Insertion Conditions and Ambulatory Recovery Quality in Sevoflurane-Based Anesthesia: A Randomized Double-Blind Placebo-Controlled Trial
Lead sponsor
Beni-Suef University
Phase
Not applicable
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
May 31, 2027
Enrollment
110 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

airway management

Arms

As registered; 2 arms.

  • Tizanidine 4 mg Active comparatorTizanidine

    Participants receive a single preoperative oral dose of tizanidine 4 mg (encapsulated in an opaque gelatin capsule) with a small sip of water (\< 30 mL) 60-90 minutes prior to induction of anesthesia.

  • Placebo Control Placebo comparatorPlacebo

    Participants receive a single preoperative oral matching placebo capsule with a small sip of water (\< 30 mL) 60-90 minutes prior to induction of anesthesia.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Proportion of Patients with Excellent Laryngeal Mask Airway (LMA) Insertion Conditions at First Attempt Immediately following the first LMA insertion attempt (approximately 1 to 3 minutes post-propofol induction)

    Evaluated immediately after the first insertion attempt using a validated 5-domain composite scale (jaw relaxation, ease of insertion, patient movement, coughing/gagging, and laryngospasm/obstruction). Each domain is scored from 1 (optimal) to 3 (worst), yielding a total composite score range of 5 (optimal) to 15 (worst). 'Excellent' insertion condition is pre-specified as a total composite score of 5 to 7.

Lead sponsor's other trials

Beni-Suef University, most recent start first.